Sana Biotechnology Q2 FY26 net loss narrows to $63.64 million; loss per share improves to $0.22 GAAP
SANA•Clinical program timeline
- Plans to file an IND and begin a Phase 1/2 trial for SC451 as early as this year; first-in-human data for SG293 in non-Hodgkin lymphoma targeted as early as this year.
- CEO Steve Harr said the company expects clinical insight on SC451 and SG293 over the next 6–9 months, if development proceeds as anticipated.
Second-quarter results and cash position
- Sana Biotechnology posted a GAAP net loss of USD 63.6 million, or USD 0.22 a share, for Q2 2026.
- Cash, cash equivalents, and marketable securities rose to USD 160.5 million as of June 30, 2026; runway expected into mid-2027.
- R&D expense increased to USD 30.7 million from USD 29.8 million a year earlier, on higher SC451 and SG293 development and CDMO costs.
